Status | Study |
Completed |
Study Name: Efficacy and Safety of Alendronate in Chinese Children or Adolescents With Osteogenesis Imperfecta Condition: Osteogenesis Imperfecta Date: 2014-11-19 Interventions: Drug: Alendronate Alendronate was administrated as 70 mg/week orally (Fosamax, Merck Sharp & Dohme |
Active, not recruiting |
Study Name: Mesenchymal Stem Cell Based Therapy for the Treatment of Osteogenesis Imperfecta Condition: Osteogenesis Imperfecta Date: 2014-06-12 Interventions: Biological: Mesenchymal Stem Cells Mesenchymal Stem Cell Infusions |
Completed |
Study Name: Translational Therapy in Patients With Osteogenesis Imperfecta - A Pilot Trial on Treatment With the Rankl-Antibody Denosumab Condition: Osteogenesis Imperfecta Date: 2013-02-14 Interventions: Drug: Denosumab Denosumab will be given subcutaneously in a dosage of 1mg/kg body weight every 12 weeks. |
Completed |
Study Name: Effect of High-Dose Vitamin D on Bone Density in Osteogenesis Imperfecta Condition: Osteogenesis Imperfecta Date: 2012-10-21 Interventions: Dietary Supplement: standard-dose vitamin D (400IU per day) |
Recruiting |
Study Name: The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta Condition: Osteogenesis Imperfecta Date: 2012-08-16 Interventions: Drug: Zoledronic acid antireso |
Completed |
Study Name: Safety, Pharmacokinetics and Pharmacodynamics of BPS804 in Osteogenesis Imperfecta Condition: Osteogenesis Imperfecta Date: 2011-08-04 Interventions: Drug: BPS804 |
Completed |
Study Name: Repeated Infusions of Mesenchymal Stromal Cells in Children With Osteogenesis Imperfecta Condition: Osteogenesis Imperfecta Type II Osteogene Date: 2010-02-01 Interventions: Biological: Mesenchymal Stromal Cells Both cohorts will receive multiple infusions of ex-vivo expanded M |
Completed |
Study Name: An Efficacy and Safety Trial of Intravenous Zoledronic Acid in Infants Less Than One Year of Age, With Severe Osteogenesis Imperfecta Condition: Osteogenesis Imperfecta Date: 2009-09-21 Interventions: Drug: Zoledronic Acid Each patient is to receive an initial dose of zoledronic acid of 0.0125 mg per kg |
Completed |
Study Name: Treatment of Severe Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation Condition: Osteogenesis Imperfecta Date: 2008-06-23 Interventions: Other: Bone Marrow Cell Transplantation Ra |
Completed |
Study Name: Marrow Mesenchymal Cell Therapy for Osteogenesis Imperfecta: A Pilot Study Condition: Osteogenesis Imperfecta Date: 2005-09-12 Interventions: Biological: Bone marrow transplant |